EnteroMedics Inc  

(Public, NASDAQ:ETRM)   Watch this stock  
Find more results for ETRM
1.42
+0.01 (0.71%)
Real-time:   11:19AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.38 - 1.43
52 week 0.99 - 2.66
Open 1.40
Vol / Avg. 161,535.00/427,427.00
Mkt cap 98.13M
P/E     -
Div/yield     -
EPS -0.40
Shares 69.10M
Beta 1.97
Inst. own 31%
Feb 10, 2015
Q4 2014 EnteroMedics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 20, 2014
EnteroMedics Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 12, 2014
Q3 2014 EnteroMedics Inc Earnings Call
Nov 12, 2014
Q3 2014 EnteroMedics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -105.87% -98.24%
Return on average equity -182.34% -194.18%
Employees 27 -
CDP Score - -

Address

2800 Patton Rd
SAINT PAUL, MN 55113-1100
United States - Map
+1-302-6587581 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

EnteroMedics Inc. (EnteroMedics) is a development- stage medical device company. The Company focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company�s neuroblocking technology, which it refers to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company�s initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. As of December 31, 2011, the Company�s enrollment and implantation in randomized, double-blind, parallel-group, multicenter pivotal clinical trial (the ReCharge trial), was completed in 233 patients at 10 centers.

Officers and directors

Mark B. Knudson Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Gregory S. Lea Chief Financial Officer, Chief Operating Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Adrianus Donders Senior Vice President - Research and Advanced Development
Age: 60
Bio & Compensation  - Reuters
Mark Bullivant Vice President - Marketing
Bio & Compensation  - Reuters
Katherine S. Tweden Ph.D. Vice President - Clinical and Regulatory
Age: 53
Bio & Compensation  - Reuters
Brad Hancock Chief Commercial Officer
Bio & Compensation  - Reuters
Anthony P. Jansz Director
Age: 53
Bio & Compensation  - Reuters
Luke B. Evnin Ph.D. Independent Director
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 53
Bio & Compensation  - Reuters
Carl S. Goldfischer M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters